Quick answer
Plan AOD-9604 by the diluent volume, and protect its disulfide. With a 5 mg vial, c = m / V sets the stock (1 mL gives 5 mg/mL, 2 mL gives 2.5 mg/mL). Avoid reducing agents, swirl instead of shaking and keep solutions cold. Published rodent studies reported oral and intraperitoneal schedules in obese animals; those parameters are summarised here for context, with no dose recommended. Supplied for laboratory research use only.
AOD-9604 is a 16-residue peptide modeled on the C-terminal region of human growth hormone (hGH 176–191), with one intramolecular disulfide bond. Anyone preparing it for laboratory work meets two separate questions: how to bring the lyophilized powder into solution without damaging the disulfide, and how to read the concentration and parameter figures that appear in published animal studies. This article takes both in turn. It is a laboratory handling guide with formula-only concentration arithmetic and a summary of what published rodent studies reported. It makes no claims beyond the laboratory bench and recommends no amount; the AOD-9604 product page states that the material is sold strictly for laboratory research use.
For compound background see the AOD-9604 research overview and the AOD-9604 explainer. Here the emphasis is on the bench.
What the product page tells you
| Item | Product page statement |
|---|---|
| Vial size | 5 mg lyophilized powder, sealed clear glass vial |
| Sequence | 16 residues modeled on the C-terminal region of hGH, labeled hGH 176–191; begins with tyrosine; two cysteines joined by one intramolecular disulfide bond |
| Molecular formula | C78H123N23O23S2 |
| Purity specification | ≥98% by HPLC; batch-specific certificates are published on the COA page |
| Storage | 2–8 °C; −20 °C long term; protect from heat, moisture and light |
| Structural note | Two cysteines joined by one disulfide bond; keep reducing agents out of the diluent unless the protocol calls for them |
The disulfide is the feature that drives the handling. A reducing agent such as dithiothreitol opens it, and so does a thiol-containing buffer additive. Free thiols can also exchange with an existing disulfide, so mixed species can form during storage in solution. Disulfide-containing peptides have been the subject of dedicated chemical-stability reviews (Manning and colleagues, 2010), and forced-degradation work lists oxidation and disulfide scrambling among the main routes for products containing this bond (Hawe and colleagues, 2012). That is the reason to avoid unnecessary additives and to keep stock times short.
Concentration arithmetic, formulas only
With a 5 mg vial, the stock concentration is set entirely by the volume of diluent added. The general relations are:
- Stock concentration: c = m / V. For the declared 5 mg, adding 1 mL gives 5 mg/mL, 2 mL gives 2.5 mg/mL and 2.5 mL gives 2 mg/mL, as the product page also lists.
- Unit conversion: 1 mg = 1,000 µg, so 2.5 mg/mL equals 2,500 µg/mL, or 250 µg per 100 µL.
- Molar concentration: cM = (m / MW) / V, using the molar mass calculated from C78H123N23O23S2. Multiply m by the peptide-content fraction if the certificate reports one.
- Dilution: C1V1 = C2V2, so V1 = C2V2 / C1.
- Mass per animal in an experimental design: mass = reported dose per kg × body weight in kg; volume to administer = mass / c. This is arithmetic for translating a published study parameter into a stock concentration for the same species in a licensed research setting, not a recommendation of a dose.
The calculator runs the same steps, and the volume calculation guide shows worked unit conversions. Write c, V, lot and date on the vial before the diluent goes in.
Reconstitution steps for a disulfide-containing peptide
- Let the cold vial reach room temperature before opening so condensation does not form on the cake.
- Choose the diluent for the experiment. A sterile diluent such as bacteriostatic water is the usual choice for a multi-entry vial; for a cell assay in which benzyl alcohol might interfere, use sterile water and divide into single-use portions.
- Check the diluent for reducing agents or thiol additives and leave them out unless the protocol calls for them.
- Direct the diluent slowly down the inner wall of the vial, not onto the powder.
- Swirl gently until the solution is clear. Do not shake; foam and shear are hard on peptides.
- Inspect against a light and a dark background. Cloudiness or particles are a reason to stop (see cloudy peptide vial after reconstitution).
- Return the solution to 2–8 °C, label with concentration and date, and divide into aliquots if it will be sampled more than a few times.
The general method is in how to reconstitute a lyophilized peptide, and diluent choices in how to mix peptides with bacteriostatic water.
What published rodent studies reported
The parameters below are taken from the abstracts of the cited papers. They describe what was done in those experiments and are given only so that a reader can see how a concentration figure is tied to a design. They are not a basis for any use outside a properly authorized animal-research protocol.
| Study | Model and compound | Route and schedule reported | What the abstract reports |
|---|---|---|---|
| Ng and colleagues, 2000 | Obese Zucker rats, AOD9604 | Oral, 500 µg/kg body weight daily for 19 days | Body-weight gain reduced by more than half versus control; increased lipolytic activity in adipose tissue; no adverse effect on insulin sensitivity by euglycemic clamp, unlike chronic intact hGH |
| Heffernan and colleagues, 2001 | Obese mice and β3-adrenergic receptor knockout mice; hGH and AOD9604 | Intraperitoneal, chronic exposure for 14 days | Reduced body weight and body fat in obese mice; increased β3-AR RNA expression; in knockout mice the long-term change in body weight and lipolysis seen in wild type was not produced, while acute energy expenditure and fat oxidation still rose |
Two things stand out from this table. First, the routes differ (oral in one, intraperitoneal in the other), so the concentration needed to deliver a given µg/kg depends on the administration volume allowed for the species and route, and a fixed stock does not suit both. Second, the authors of the 2001 paper concluded that the lipolytic actions of both compounds are not mediated directly through the β3 receptor, even though both increased its expression. That is an example of how the published mechanism is more nuanced than a one-line description such as "stimulates lipolysis" suggests.
A related 2000 paper in the American Journal of Physiology studied a differently named synthetic hGH fragment, AOD-9401, in ob/ob mice given orally for 30 days (Heffernan and colleagues, 2000). It is cited here as context, not as data on AOD-9604 itself; check the sequence of any compound before comparing results across papers.
Planning concentrations for an in vitro lipolysis assay
Cell and tissue assays usually work in molar units. A reasonable workflow is to prepare a molar stock, make intermediate dilutions in assay buffer, and add them to wells so that the final solvent and buffer composition is identical across conditions, including vehicle controls. Because no single published concentration is endorsed here, a range-finding series spanning several orders of magnitude, run with replicate wells and a vehicle control, is the standard way to locate a response. Adipocyte lipolysis assays commonly read out glycerol or free fatty acid release; any such readout should be run with a positive control for lipolysis so that assay failure can be distinguished from a null result.
| Design element | Reason |
|---|---|
| Vehicle control matched to every component of the stock | Separates peptide effect from diluent effect |
| Positive control for lipolysis | Shows the assay can respond |
| Concentration series, not a single point | Allows a response curve to be fitted |
| Fresh dilution on the day | Dilute peptide solutions lose material to surfaces and may degrade |
| Low-binding tubes | Peptide adsorption to glass and plastic depends on the peptide and the surface (Goebel-Stengel and colleagues, 2011) |
Keeping a reconstituted stock
The product page tells you how to keep the powder: 2–8 °C, −20 °C for a long hold, away from heat, moisture and light. After reconstitution the page says to return the solution to 2–8 °C, label it and divide it into aliquots if it will be sampled more than a few times. Beyond that no validated shelf life for AOD-9604 in solution has been published, so none is stated here. The dry state is generally far more stable than solution (Manning and colleagues, 2010), and freezing is itself a stress that concentrates solutes as ice forms (Bhatnagar and colleagues, 2007), so freeze small single-use portions, not a large stock. See also how long do reconstituted peptides last and storing research peptides.
Verification before you start
Match the lot string on the vial to a published certificate where there is one, and record when there is not. The COA page lists what is available, and AOD-9604 purity testing explains what a chromatogram for a disulfide-containing peptide should look like. A reduced form and a scrambled form can run close to the intact peptide on HPLC, so a mass check is worth having if the intact disulfide is essential to your experiment.
Related reading
- AOD-9604 research overview
- AOD-9604 peptide explained
- AOD-9604 purity testing
- Peptide reconstitution volume calculations
- AOD-9604 product page
Frequently asked questions
What diluent should be used for AOD-9604?
The product page says a sterile diluent such as bacteriostatic water is the usual choice for multi-use vials. For cell assays where benzyl alcohol could interfere, sterile water with single-use portions is an alternative. Keep reducing agents out unless the protocol calls for them.
Why avoid reducing agents with AOD-9604?
The peptide contains two cysteines joined by one disulfide bond. Reducing agents or thiol additives can open or exchange that bond and change the molecule.
How do I calculate stock concentration from a 5 mg vial?
Use c = m / V. Adding 1 mL gives 5 mg/mL, 2 mL gives 2.5 mg/mL and 2.5 mL gives 2 mg/mL, as listed on the product page. The calculator confirms any other volume.
What did Ng and colleagues report in obese Zucker rats?
The abstract reports oral AOD9604 at 500 µg/kg body weight daily for 19 days, with body-weight gain reduced by more than half, increased lipolytic activity in adipose tissue, and no adverse effect on insulin sensitivity by euglycemic clamp.
What did the 2001 Endocrinology study report about the β3 receptor?
Both hGH and AOD9604 increased β3-adrenergic receptor RNA in obese mice, but long-term effects were not produced in β3 knockout mice, and the authors concluded the lipolytic actions are not directly mediated through that receptor.
Is AOD-9604 the same as AOD-9401?
No. The 2000 American Journal of Physiology paper studied AOD-9401, a different synthetic hGH fragment. Check the sequence before comparing results between papers.
How is lyophilized AOD-9604 stored?
The product page states 2–8 °C, −20 °C for long-term storage, and protection from heat, moisture and light.
Is there a published shelf life for AOD-9604 in solution?
No validated shelf life was found. General practice is to keep solutions at 2–8 °C, label them, divide into aliquots and limit time in solution.
Does this article give a dose?
No. It describes what published rodent studies reported and gives concentration arithmetic as formulas. It does not recommend any dose or use.
Is AOD-9604 from V8 for use in people or animals?
No. It is sold strictly for laboratory research use only.
Related reading: AOD-9604 in Rodent Models: Obese Mice and Zucker Rats, AOD-9604 Purity: Disulfide Quality and COA Checks, AOD-9604 Preclinical Literature: Study by Study.
References
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. doi:10.1159/000053183
- Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;279(3):E501-E507. doi:10.1152/ajpendo.2000.279.3.e501
- Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. doi:10.1210/endo.142.12.8522
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
- Hawe A, Wiggenhorn M, van de Weert M, Garbe JHO, Mahler HC, Jiskoot W. Forced degradation of therapeutic proteins. J Pharm Sci. 2012;101(3):895-913. doi:10.1002/jps.22812
- Bhatnagar BS, Bogner RH, Pikal MJ. Protein stability during freezing: separation of stresses and mechanisms of stabilization. Pharm Dev Technol. 2007;12(5):505-523. doi:10.1080/10837450701481157
- Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
